The management of localized gastric cancer has evolved globally to region-specific approaches with little convergence. The unifying theme, however, is that surgery alone is insufficient for best outcomes, and adjunctive therapy must be offered. Multidisciplinary evaluation before therapy is highly recommended, but postoperative approaches are not conducive to this scenario.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Macdonald, J. S. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl J. Med. 345, 725–730 (2001).
Cunningham, D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11–20 (2006).
Sakuramoto, S. et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357, 1810–1820 (2007).
Bang, Y. J. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379, 315–321 (2012).
Lee, J. et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST Trial. J. Clin. Oncol. 30, 268–273 (2012).
Sasako, M. et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. 29, 4387–4393 (2011).
Kattan, M. W., Karpeh, M. S., Mazumdar, M. & Brennan, M. F. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J. Clin. Oncol. 21, 3647–3650 (2003).
Ajani, J. A., Blum, M. A., Estrella, J. S., Das, P. & Fournier, K. F. Gastric cancer: apples will always be apples. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2011.40.9607.
Cho, J. Y. et al. Gene expression signature-based prognostic risk score in gastric cancer. Clin. Cancer Res. 17, 1850–1857 (2011).
Tan, I. B. et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 141, 476–485.e411 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Blum, M., Ajani, J. Localized gastric cancer—a CLASSIC shift in the paradigm?. Nat Rev Gastroenterol Hepatol 9, 194–195 (2012). https://doi.org/10.1038/nrgastro.2012.35
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2012.35
